Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients
Authors:
- 1 March 2010
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 138 (3) , 913-921
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Expert opinion on the treatment of patients with chronic hepatitis CJournal of Viral Hepatitis, 2009
- Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patientsJournal of Hepatology, 2008
- Immune responses during acute and chronic infection with hepatitis C virusClinical Immunology, 2008
- SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 NonrespondersGastroenterology, 2007
- Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized StudyGastroenterology, 2006
- Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studiesJournal of Viral Hepatitis, 2005
- An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virusNature, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001